CombinatoRx's Oncology Collaboration with Novartis
Taskin Ahmed
Abstract
CombinatoRx Inc. announced an oncology collaboration with Novartis AG, the Swiss drug giant, that will yield CombinatoRx an up-front payment of US$4 M.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.